FINE: Imaging fibrosis in lung cancer and relating findings to outcomes of treatment

Imaging Fibroblast Activation Protein (FAP) in non-small cell lung cancer using PET scan and correlation with outcomes of usual therapy.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN13047154

Enrollment

Registered

2022-02-15

Start date

2021-11-19

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer Cancer

Interventions

Eligible participants from both cohorts, will undergo a research scan (PET-CT scan using the FAP radiotracer) and it is possible the eligibility assessment/consent occur on the same day as the scan.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Capacity to provide informed consent 2. Confirmed lung cancer for which surgical resection is being planned (Cohort 1) 3. Confirmed lung cancer (cohort 2) planned for systemic oncological treatment 4. Treatment naïve patients =50 years 5. Thoracic CT scan taken within the previous 12 weeks 6. ECOG performance status 0-2

Exclusion criteria

Exclusion criteria: 1. Inability or unwilling to give informed consent. 2. Unable to tolerate the supine position 3. Impaired renal function with eGFR of <30 mL/min/1.73m² 4. Severe or significant comorbidity that prevents systemic oncological therapy or performance status 3 or 4 5. Women who are pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame
Cohort 1 (measured at the time of resection): 1. The degree of fibrosis on the 68Ga-FAPI scan measured by SUV (standardised uptake volume) over a ROI (region of interest) 2. Markers of fibroblast activation from the excised tissue (measured by multiparametric flow cytometry analysis), including FAP, CD34, aSMA, podoplanin) Cohort 2: 1. The degree of fibrosis on the 68Ga-FAPI scan measured by SUV (standardised uptake volume) over a ROI (region of interest) measured at the time of resection 2. Treatment response measured by visual inspection of CT scan using RECIST and iRECIST methods post treatment and on usual scans up to 1 year	—

Measure

Time frame

Cohort 1 (measured at the time of resection): 1. The degree of fibrosis on the 68Ga-FAPI scan measured by SUV (standardised uptake volume) over a ROI (region of interest) 2. Markers of fibroblast activation from the excised tissue (measured by multiparametric flow cytometry analysis), including FAP, CD34, aSMA, podoplanin) Cohort 2: 1. The degree of fibrosis on the 68Ga-FAPI scan measured by SUV (standardised uptake volume) over a ROI (region of interest) measured at the time of resection 2. Treatment response measured by visual inspection of CT scan using RECIST and iRECIST methods post treatment and on usual scans up to 1 year

—

Secondary

Measure	Time frame
Cohort 1: Laboratory markers including T-cell phenotypes within the tumour measured using biopsy at the time of resection Cohort 2: Progression free survival and mortality measured using patient records up to 1 year	—

Countries

Scotland, United Kingdom

Contacts

Public ContactKatie Hamilton

k.hamilton@ed.ac.uk+44 (0)131 2429180

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026